Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis
This article was originally published in The Pink Sheet Daily
Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
The latest drug development news and highlights from our US FDA Performance Tracker.
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.